<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02605421</url>
  </required_header>
  <id_info>
    <org_study_id>2015LS108</org_study_id>
    <nct_id>NCT02605421</nct_id>
  </id_info>
  <brief_title>Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma</brief_title>
  <official_title>Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II single center study to administer two courses of myeloablative&#xD;
      consolidation chemotherapy each followed by an autologous peripheral blood stem cell (PBSC)&#xD;
      rescue in patients with high-risk neuroblastoma who have completed induction chemotherapy&#xD;
      (independent of this study). Ideally, patients should begin consolidation chemotherapy no&#xD;
      later than 8 weeks after the start of Induction Cycle #5; however it is strongly recommended&#xD;
      to begin consolidation within 4-6 weeks after the start of Induction Cycle #5.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>3 years from first PBSC infusion</time_frame>
    <description>Percentage of patients with progression free survial. Kaplan-Meier curves and 95% confidence intervals will be used to estimate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Engraftment</measure>
    <time_frame>Day 42</time_frame>
    <description>Defined as an absolute neutrophil count (ANC) greater than or equal to 0.5 x 109/L for three consecutive days by day 42 after first transplant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse</measure>
    <time_frame>3 years from first PBSC infusion</time_frame>
    <description>Percentage of patients with relapse. Relapse will be defined as any new lesion; increase of any measurable lesion by &gt;25%; previous negative bone is positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years from first PBSC infusion</time_frame>
    <description>Kaplan-Meier curves and 95% confidence intervals will be used to estimate overall survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Consolidation course #1 consists of thiotepa and cyclophosphamide followed by a PBSC rescue. Consolidation course #2 consists of melphalan, etoposide and carboplatin followed by a second PBSC rescue. Post infusion, patients will receive Granulocyte-Colony Stimulating Factor beginning on Day 0 of each consolidation course.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan by IV once daily for 3 doses on Days -8, -7, and -6. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Etoposide by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin by IV once daily for 4 doses on Days -8, -7, -6 and -5. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Stem Cell Infusion</intervention_name>
    <description>On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Granulocyte colony stimulating factor</intervention_name>
    <description>Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC &gt; 2000/μL for 3 consecutive days.</description>
    <arm_group_label>Patients Treated for Neuroblastoma</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Less than 30 years of age at diagnosis of neuroblastoma&#xD;
&#xD;
          -  End of Induction disease evaluation demonstrating CR, PR, MR or SD&#xD;
&#xD;
          -  Hematopoietic Recovery from last induction course of chemotherapy&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  Minimum frozen PBSCs of 2 x 10^6 CD34 cells/kg for each transplant are mandatory and a&#xD;
             PBSC of 2 x 10^6 CD34 cells/kg for back-up are strongly recommended (thus, PBSC of no&#xD;
             less than 6 x 10^6 CD34 cells/kg is encouraged). These must all be collected prior to&#xD;
             the initiation of consolidation.&#xD;
&#xD;
          -  Adequate organ function defined as:&#xD;
&#xD;
               -  Hepatic: AST and ALT &lt; 3 x upper limit of institutional normal; ALT ≤ 3 x ULN for&#xD;
                  age; total bilirubin ≤ 1.5 x ULN for age, if baseline was normal, &gt; 1.0 1.5 x&#xD;
                  baseline if baseline was abnormal&#xD;
&#xD;
               -  Cardiac: shortening fraction ≥ 27% or ejection fraction ≥ 45%, no clinical&#xD;
                  congestive heart failure&#xD;
&#xD;
               -  Pulmonary: no evidence of dyspnea at rest and norequirement for supplemental&#xD;
                  oxygen&#xD;
&#xD;
               -  Renal: Creatinine clearance or GFR &gt; 60 mL/min/1.73m^2. If a creatinine clearance&#xD;
                  is performed at end induction and the result is &lt; 100 ml/min/1.73m^2, a GFR must&#xD;
                  then be performed using a nuclear blood sampling method or iothalamate clearance&#xD;
                  method. Camera method is NOT allowed as measure of GFR prior to or during&#xD;
                  Consolidation therapy for patients with GFR or creatinine clearance of &lt; 100&#xD;
                  ml/min/1.73m^2&#xD;
&#xD;
          -  Recovery from acute toxicities of last cycle of induction chemotherapy&#xD;
&#xD;
          -  Appropriate written consent - adult or parent/guardian if patient is &lt; 18 years of age&#xD;
             and minor information sheet if patient is &gt; 8 years of age&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashish Gupta, MBBS, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Burke</last_name>
    <phone>612-273-8482</phone>
    <email>lburke3@Fairview.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashish Gupta, MBBS, MPH</last_name>
    <phone>612-626-2961</phone>
    <email>stef0030@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Burke, RN</last_name>
      <phone>612-273-8482</phone>
      <email>lburke3@Fairview.org</email>
    </contact>
    <investigator>
      <last_name>Ashish Gupta, MBBS, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 12, 2015</study_first_submitted>
  <study_first_submitted_qc>November 12, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2015</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-risk neuroblastoma</keyword>
  <keyword>Neuroblastoma</keyword>
  <keyword>Myeloablative chemotherapy</keyword>
  <keyword>Myeloablative consolidation chemotherapy</keyword>
  <keyword>Autologous peripheral blood stem cell rescue</keyword>
  <keyword>PBSC</keyword>
  <keyword>Autologous stem cell rescue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

